drugset

drugset / Trial / NCT00307658

Intravenous Immunoglobulin After Relapse in Vasculitis

NCT00307658 ↗

Phase 3 Terminated 40 enrolled Assistance Publique - Hôpitaux de Paris

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of this study is to study the efficacy of intravenous immunoglobulins for inducing remission in patients relapsing of systemic vasculitides.

Timeline

Start: 2001-03
Primary completion: —
Completion: 2006-07

Publications

Martinez V, Cohen P, Pagnoux C, Vinzio S, Mahr A, Mouthon L, Sailler L, Delaunay C, Sadoun A, Guillevin L; French Vasculitis Study Group. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients. Arthritis Rheum. 2008 Jan;58(1):308-17. doi: 10.1002/art.23147.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	human immunoglobulins G	Unknown	0.5 g/kg	Intravenous

Indications